| APG115 | Small molecule | salivary gland cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | melanoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | multiple myeloma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | chronic myelomonocytic leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | soft tissue sarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | glioblastoma multiforme | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | primary myelofibrosis | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | myelofibrosis | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Active, not recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | breast cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | plasmacytoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | follicular lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIREMADLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | liver disease | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | Uveal Melanoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Not yet recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | neoplasm | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| APG115 | Small molecule | liposarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | colorectal carcinoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | essential thrombocythemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | non-Hodgkins lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | diffuse large B-cell lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | Merkel cell skin cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 3.0 | Terminated | ClinicalTrials |
| NAVTEMADLIN | Small molecule | gliosarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Suspended | ClinicalTrials |
| NAVTEMADLIN | Small molecule | small cell lung carcinoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | liposarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| SIREMADLIN | Small molecule | myelofibrosis | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | myeloproliferative disorder | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | cancer | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| APG115 | Small molecule | lymphoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| IDASANUTLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Terminated | ClinicalTrials |
| IDASANUTLIN | Small molecule | multiple myeloma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Active, not recruiting | ClinicalTrials |
| SIREMADLIN | Small molecule | soft tissue sarcoma | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | lymphoid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| APG115 | Small molecule | myelodysplastic syndrome | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | chronic myelogenous leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |
| NAVTEMADLIN | Small molecule | polycythemia vera | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 2.0 | Recruiting | ClinicalTrials |
| IDASANUTLIN | Small molecule | essential thrombocythemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Completed | ClinicalTrials |
| NAVTEMADLIN | Small molecule | therapy related acute myeloid leukemia and myelodysplastic syndrome | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Suspended | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Withdrawn | ClinicalTrials |
| SIREMADLIN | Small molecule | acute myeloid leukemia | Tumour suppressor p53/oncoprotein Mdm2 inhibitor | 1.0 | Recruiting | ClinicalTrials |